BeyondSpring Inc. Debt Securities, Available-for-sale, Amortized Cost
BeyondSpring Inc. (BYSI) had Debt Securities, Available-for-sale, Amortized Cost of $141.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-11-12
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $141.00K.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $1.65M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-09-30 | $141.00K 10-Q · filed 2025-11-12 |
| 2021-09-30 | $1.65M 6-K · filed 2021-12-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |